Short answer
Syndax Pharmaceuticals Inc (SNDX) filed an 8-K current report with the SEC on April 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 text contains only an incorporation-by-reference disclaimer.
Syndax Pharmaceuticals Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 text contains only an incorporation-by-reference disclaimer
- No earnings period, financial results, or operating metrics disclosed in the provided excerpt
Item EX-99.1 · Exhibit EX-99.1
- 1Q26 revenue $64.9M, up 224% YoY, driven by Revuforj product revenue $48.9M and Niktimvo collaboration revenue $15.9M
- Revuforj revenue rose 144% YoY and 11% sequentially, with prescriptions up approximately 160% YoY
- Niktimvo net sales reached $55.1M; Syndax recorded 50% profit share as $15.9M collaboration revenue
- Net loss narrowed to $42.7M, or $0.48 per share, from $84.8M, or $0.98, in 1Q25
- Cash, equivalents, and short-term investments totaled $352.1M; 2026 operating expense guidance approximately $400M excluding $50M stock compensation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Syndax Pharmaceuticals Inc 8-K filings
Get the next SNDX 8-K as it lands
Follow SNDX for push alerts, or ask the research agent what this filing means.